

BIO KEY INTERNATIONAL INC  
Form 8-K/A  
October 31, 2018  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 22, 2018

**BIO-KEY INTERNATIONAL, INC.**

(Exact name of registrant as specified in its charter)

|                                 |                  |                   |
|---------------------------------|------------------|-------------------|
| <b>Delaware</b>                 | <b>001-13463</b> | <b>41-1741861</b> |
| (State or other jurisdiction of | (Commission File | (I.R.S.           |
| incorporation)                  | Number)          | Employer          |
|                                 |                  | Identification    |
|                                 |                  | No.)              |

**3349 Highway 138, Building A, Suite E**

**Wall, NJ 07719**

(Address of principal executive offices) (Zip Code)

**(732) 359-1100**

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 8-K/A

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

## Explanatory Note

This Current Report on Form 8-K/A (this "Amendment") is being filed as an amendment to the Current Report on Form 8-K filed by BIO-key International, Inc. (the "Company") on June 27, 2018 (the "Original 8-K"). The Original 8-K was filed with the Securities and Exchange Commission (the "SEC") to report the results of the matters submitted to a vote by the Company's stockholders at the Company's Annual Meeting of Stockholders held on June 22, 2018 (the "Annual Meeting"). The sole purpose of this Amendment is to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company's decision as to how frequently the Company will conduct future shareholder advisory votes regarding named executive officer compensation. Except as set forth herein, no other modifications have been made to the Original 8-K.

### Item 5.07 Submission of Matters to a Vote of Security Holders.

(d) At the Annual Meeting, the Company's shareholders voted on, among other matters, an advisory proposal concerning the frequency of future advisory votes on named executive officer compensation. As reported in the Original 8-K, the Company's shareholders approved, on an advisory basis, "three years" as the frequency for holding an advisory vote on the compensation of the Company's named executive officers. The recommendation of the Board of Directors of the Company as set forth in the Company's proxy statement filed with the SEC on April 30, 2018 was to approve named executive officer compensation every year. Consistent with the recommendation of the Board of Directors of the Company, the Company has determined to hold the advisory vote on the compensation of the Company's named executive officers every year until the next required vote on the frequency of the advisory vote on the compensation of the Company's named executive officers.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-key International, Inc.

Date: October 31, 2018

By: /s/ Cecilia Welch  
Cecilia Welch  
Chief Financial Officer

